Telmisartan-induced sprue-like enteropathy: a case report. Issue 1 (25th September 2018)

• Record Type: Journal Article
• Authors: Alzueta, Natalia; Echeverría, Amaya; Sanz, Lorea; Fontela, Carmen; Acín, Teresa; Montenegro, Lidia; Garjón, Javier
• Is Part Of: European journal of hospital pharmacy. Volume 27:Issue 1(2020)
• Page Start: 49
• Page End: 51
• Publication Date: 2018-09-25
• Subjects: adverse event -- sprue-like enteropathy -- diarrhea -- telmisartan -- angiotensin-receptor Ii blocker; Pharmacy -- Periodicals; Hospital pharmacies -- Periodicals; 615.1
• DOI: 10.1136/ejhpharm-2018-001669
• Languages: English
• ISSNs: 2047-9956

Abstract

Abstract : A possible case of sprue-like enteropathy (SLE) induced by the use of telmisartan is reported. Telmisartan is an angiotensin-receptor II blocker (type 1) used for the treatment of hypertension. Several cases of SLE associated with olmesartan and other drugs of the same group have been reported. In all cases, SLE resolved following therapy withdrawal. We describe the case of an 80-year-old woman who presented with diarrhoea and abdominal pain. In the past 5 years she had been treated with telmisartan 40 mg once a day for hypertension, so we hypothesised that symptoms might be caused by telmisartan. After treatment discontinuation, diarrhoea disappeared. Three causality algorithms were applied and revealed a possible or likely causal relationship. At present, the patient remains asymptomatic. There is a causal relationship between the use of telmisartan and SLE. This association should be taken into account by physicians when prescribing and reviewing drug therapies.